TipRanks
Go Ultimate55% OFF

Can-Fite BioPharma (CANF) Stock Forecast & Price Target

660 Followers
See the Price Targets and Ratings of:

CANF Analyst Ratings

Moderate Buy
1Ratings
1Buy0Hold0Sell
Based on 1 analysts giving stock ratings to Can-Fite BioPharma in the past 3 months

CANF Stock 12 Month Forecast

$8.00▲(393.83% Upside)
Based on 1 Wall Street analysts offering 12 month price targets for Can-Fite BioPharma in the last 3 months. The average price target is $8.00 with a high forecast of $8.00 and a low forecast of $8.00. The average price target represents a 393.83% change from the last price of $1.62.
Highest Price Target$8.00Average Price Target$8.00Lowest Price Target$8.00

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for CANF
Price TargetFollowArticle
H.C. Wainwright$8buy393.83%UpsideReiterated09/29/26
D. Boral Capital$7buy332.10%UpsideUpgraded05/13/26
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRVITrevi Therapeutics
EHCEncompass Health
MDWDMediwound
OVIDOvid Therapeutics
ONCBeOne Medicines

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Can-Fite BioPharma

3 Months
Jason Kolbert
Jason KolbertD. Boral Capital
Success Rate11/34 ratings generated profit
32%
Average Return
-9.66%

Copying Jason Kolbert's trades and holding each position for 3 Months would result in 32.35% of your transactions generating a profit, with an average return of -9.66% per trade.

1 Year
Jason Kolbert
Jason KolbertD. Boral Capital
Success Rate4/34 ratings generated profit
12%
Average Return
-44.57%

Copying Jason Kolbert's trades and holding each position for 1 Year would result in 11.76% of your transactions generating a profit, with an average return of -44.57% per trade.

2 Years
Jason Kolbert
Jason KolbertD. Boral Capital
Success Rate0/34 ratings generated profit
0%
Average Return
-68.27%

Copying Jason Kolbert's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -68.27% per trade.

CANF Analyst Recommendation Trends

01234Nov 25Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26
Monthly rating counts for CANF
RatingJun 26Jul 26Aug 26Sep 26Oct 26
Strong Buy21211
Buy10000
Hold00000
Sell00000
Strong Sell00000
total31211

In the current month, CANF has received 1 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CANF average Analyst price target in the past 3 months is 8.00.

CANF Financial Forecast

$-7$-5.25$-3.5$-1.75$0Q3 2025Q2 2026Q4 2026
High$-0.80
Consensus$-0.80
Low$-0.80

CANF Earnings Forecast

Next quarter’s earnings estimate for CANF is -$0.80 with a range of -$0.80 to -$0.80. The previous quarter’s EPS was -$1.24. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.

$201,999$202,547$203,095$203,643$204,191Q3 2025Q2 2026Q4 2026
High$202K
Consensus$202K
Low$202K

CANF Sales Forecast

Next quarter’s sales forecast for CANF is $202.00K with a range of $202.00K to $202.00K. The previous quarter’s sales results were $203.40K. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

CANF Stock Forecast FAQ

What is CANF’s average 12-month price target, according to analysts?
Based on analyst ratings, Can-Fite BioPharma’s 12-month average price target is $8.00.
What is CANF’s upside potential, based on the analysts’ average price target?
Can-Fite BioPharma has 393.83% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CANF a Buy, Sell or Hold?
Can-Fite BioPharma has a consensus rating of Moderate Buy which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
What is Can-Fite BioPharma’s price target?
The average price target for Can-Fite BioPharma is $8.00. This is based on 1 12-month price targets, issued in the past 3 months. The highest analyst price target is $8.00, the lowest forecast is $8.00. The average price target represents a 393.83% increase from the current price of $1.62.
What do analysts say about Can-Fite BioPharma?
Can-Fite BioPharma’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Street analysts.
How can I buy shares of CANF?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.